Clene to Present Neurodegenerative Disease Research at Prestigious Technology Conference

Clene Inc., a clinical-stage biopharmaceutical company specializing in neurodegenerative disease treatments, will present its research and strategic initiatives at the upcoming Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025. The conference, hosted at The Venetian Resort in Las Vegas, Nevada, will provide a critical platform for the company to connect with institutional investors and showcase its groundbreaking work in neurological disease research.

The conference, organized by JonesTrading and supported by B2i Digital, Inc., offers a unique environment for direct interaction between corporate leadership and potential investors. Clene's CEO and President, Rob Etherington, will participate in various conference activities, including one-on-one meetings, fireside chats, and panel discussions aimed at highlighting the company's progress in developing innovative treatments for conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis.

The event will feature keynote addresses from notable speakers, including Dr. Charity Dean, CEO of PHC Global, and Eric F. Trump, Executive Vice President of The Trump Organization. These presentations are expected to provide broader context for technological and medical innovations in the healthcare sector.

Clene's participation represents a significant opportunity to communicate its scientific advancements, particularly its investigational therapy CNM-Au8®, which targets mitochondrial function and the NAD pathway to potentially improve neuronal survival and reduce oxidative stress. The conference serves as a critical venue for the company to raise awareness about its research and attract potential investment and partnerships.

The technology and innovation conference underscores the growing importance of direct communication between emerging biotech companies and the investment community. By providing a platform for in-depth discussions, the event facilitates potential collaborations and funding opportunities that could accelerate medical research and development.